Clinical Report: Exosomes from hUCMSC Influence Renal Injury in IgA Nephropathy

Overview

This study investigates the effects of human umbilical cord mesenchymal stem cell-derived exosomes (hUCMSC-Exos) on renal injury markers, gut microbiota diversity, and inflammatory pathways in an IgA nephropathy (IgAN) mouse model. Findings suggest that hUCMSC-Exos may improve renal function and alter gut microbiota composition, indicating a potential therapeutic avenue for IgAN.

Background

IgA nephropathy (IgAN) is the most common primary glomerulonephritis and a significant cause of end-stage kidney disease, with limited treatment options available. Recent research highlights the role of gut microbiota dysbiosis and innate immune activation in IgAN pathogenesis, suggesting a complex interplay between the gut and kidney. Understanding these mechanisms could lead to novel therapeutic strategies targeting both renal and gut health.

Data Highlights

Key Findings

• hUCMSC-Exos improved renal injury markers in an IgAN-like mouse model.
• Administration of hUCMSC-Exos altered gut microbiota composition, enriching beneficial bacterial taxa.
• Microbiome analysis revealed correlations between specific taxa and renal dysfunction indicators.
• Transcriptomic analysis indicated altered expression of NLRP3 inflammasome-related genes in human IgAN glomeruli.
• In vitro studies showed reduced levels of inflammatory markers (NLRP3, IL-1β, IL-18) in podocytes exposed to hUCMSC-Exos.

Clinical Implications

The findings suggest that hUCMSC-Exos may serve as a potential therapeutic agent in managing IgAN by improving renal function and modulating gut microbiota. Clinicians should consider the gut-kidney axis in treatment strategies for IgAN, as targeting microbiota may enhance patient outcomes.

Conclusion

hUCMSC-Exos are associated with beneficial changes in renal injury markers and gut microbiota in an IgAN model, highlighting their potential as a therapeutic candidate. Further research is warranted to explore the causal mechanisms underlying these associations.

Related Resources & Content

1. Frontiers in Immunology, 2026 -- Exosomes in inflammatory tissue injury: key pathogenic factors and promising therapeutic agents
2. Journal of Gastroenterology, 2019 -- The Role of Mesenchymal Stem Cell Secretome in Acellular Regenerative Approaches for Liver Disorders
3. Archives of Toxicology, 2025 -- Effects of nephrotoxic agents and oxidative stress on the viability and transport capabilities of renal proximal tubular cells derived from human induced pluripotent stem cells
4. KDIGO, 2025 -- Executive summary of the KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN)
5. Frontiers in Immunology — Mesenchymal stem cell alleviate concanavalin A-induced hepatitis via immune reprogramming and complement regulation
6. Role of the gut microbiota in the pathogenesis of IgA nephropathy
7. Executive summary of the KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV)
8. Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial - ScienceDirect